Meghan Mullen Dickman, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 3 carriers
- Offices
- 5
Offices
5 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
14 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dickman’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A126496 · Current
Licensed to practise in California · since 2013 · expires 2027-03-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$291,511
Medicare paid this office $291,511 for 1,013 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 423 | $59,343 | $104 |
| Short return visit (20+ min) | 461 | $39,137 | $72 |
| Destruction of precancer skin growth, 1 growth | 552 | $33,234 | $50 |
| Biopsy of related skin growth, first growth | 219 | $22,274 | $86 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 65 | $18,868 | $286 |
See all 22 services
| Return visit (30+ min) | 423 | $59,343 | $104 |
| Short return visit (20+ min) | 461 | $39,137 | $72 |
| Destruction of precancer skin growth, 1 growth | 552 | $33,234 | $50 |
| Biopsy of related skin growth, first growth | 219 | $22,274 | $86 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 65 | $18,868 | $286 |
| Destruction of skin growth, 1-14 growths | 152 | $18,414 | $110 |
| Destruction of precancer skin growth, 2-14 growths | 449 | $16,226 | $7 |
| New patient visit (45+ min) | 82 | $11,663 | $142 |
| New patient visit (30+ min) | 123 | $11,479 | $93 |
| Destruction of precancer skin growth, 15 or more growths | 49 | $9,285 | $150 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 12 | $5,425 | None |
| Punch biopsy, first skin growth | 43 | $4,457 | $104 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 33 | $4,067 | $123 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 27 | $3,753 | $139 |
| Biopsy of related skin growth, each additional growth | 42 | $3,188 | $51 |
| Application of light to destroy precancer skin growth | 13 | $1,975 | $152 |
| Injection into skin growth, 1-7 growths | 14 | $1,132 | $47 |
| New patient visit (15+ min) | 15 | $840 | $56 |
| Short return visit | 15 | $679 | $42 |
| Punch biopsy, each additional skin growth | 11 | $551 | $46 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 12 | $193 | $15 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 16 | $35 | None |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 41 | More than 84% of doctors who do this |
| Removal of skin lesions | 1278 | More than 95% of doctors who do this |
| Removal or shaving of skin growth | 43 | More than 78% of doctors who do this |
| Skin biopsy | 289 | More than 90% of doctors who do this |
Who their Medicare patients are
1,013 Original Medicare patients in 2024. Average age 75 · Under 65 4% · 85 and older 10% · Women 57% · Also on Medicaid 9% · Health risk score 1.05. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 69% · Chronic kidney disease 22% · Diabetes 21% · Coronary heart disease 21% · Cancer 20% · Atrial fibrillation 15% · Depression 13% · Heart failure 11% · COPD 11% · Stroke 7% · Dementia 4%.
The office billed $1,393,511, Medicare allowed $405,306 and paid $291,511; for 5,809 services of 47 kinds; $5,460 of it was for drugs given in the office and $286,051 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,013 | 5,809 | 75 | 1.05 | $1,393,511 | $291,511 |
| 2023 | 920 | 5,600 | 74 | 1.08 | $1,267,066 | $289,091 |
| 2022 | 759 | 5,084 | 73 | 1.08 | $1,137,208 | $255,849 |
| 2021 | 831 | 5,004 | 73 | 1.13 | $1,117,662 | $258,286 |
| 2020 | 774 | 4,203 | 74 | 1.27 | $861,602 | $176,348 |
| 2019 | 723 | 3,706 | 73 | 1.31 | $742,962 | $164,295 |
| 2018 | 459 | 1,980 | 73 | 1.19 | $386,847 | $88,624 |
| 2017 | 357 | 1,531 | 73 | 1.14 | $259,266 | $63,045 |
| 2016 | 82 | 182 | 71 | 1.13 | $23,471 | $7,354 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 22 services
| Return visit (30+ min) | 338 | $51,374 | $111 |
| Short return visit (20+ min) | 436 | $42,883 | $78 |
| Destruction of precancer skin growth, 1 growth | 467 | $31,313 | $52 |
| Biopsy of related skin growth, first growth | 189 | $22,340 | $98 |
| Destruction of precancer skin growth, 2-14 growths | 387 | $17,366 | $7 |
| Destruction of precancer skin growth, 15 or more growths | 70 | $16,334 | $163 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 45 | $14,792 | $308 |
| New patient visit (30+ min) | 146 | $13,336 | $91 |
| New patient visit (45+ min) | 94 | $12,907 | $137 |
| Destruction of skin growth, 1-14 growths | 84 | $10,141 | $111 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 17 | $8,014 | None |
| Punch biopsy, first skin growth | 40 | $4,914 | $123 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 28 | $3,999 | $125 |
| Biopsy of related skin growth, each additional growth | 46 | $3,708 | $52 |
| Application of light to destroy precancer skin growth | 18 | $3,141 | $157 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 14 | $1,921 | $137 |
| New patient visit (15+ min) | 31 | $1,662 | $54 |
| Short return visit | 25 | $1,158 | $46 |
| Telehealth originating site facility fee | 47 | $1,026 | $21 |
| Punch biopsy, each additional skin growth | 14 | $921 | $61 |
| Injection into skin growth, 1-7 growths | 14 | $757 | $45 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 22 | $27 | None |
2022: 21 services
| Return visit (30+ min) | 280 | $42,809 | $106 |
| Short return visit (20+ min) | 380 | $37,406 | $76 |
| Destruction of precancer skin growth, 1 growth | 407 | $27,997 | $50 |
| Biopsy of related skin growth, first growth | 212 | $22,745 | $90 |
| Destruction of precancer skin growth, 2-14 growths | 322 | $15,572 | $7 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 22 | $12,421 | None |
| Destruction of precancer skin growth, 15 or more growths | 54 | $11,904 | $153 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 36 | $10,908 | $295 |
| New patient visit (30+ min) | 123 | $10,491 | $85 |
| New patient visit (45+ min) | 75 | $9,350 | $125 |
| Destruction of skin growth, 1-14 growths | 64 | $7,594 | $104 |
| Punch biopsy, first skin growth | 51 | $6,309 | $117 |
| Biopsy of related skin growth, each additional growth | 61 | $4,276 | $52 |
| Application of light to destroy precancer skin growth | 22 | $4,246 | $157 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 21 | $2,573 | $123 |
| Short return visit | 46 | $2,232 | $49 |
| New patient visit (15+ min) | 39 | $2,086 | $53 |
| Punch biopsy, each additional skin growth | 20 | $1,398 | $61 |
| Injection into skin growth, 1-7 growths | 24 | $1,275 | $43 |
| Telehealth originating site facility fee | 52 | $1,022 | $17 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 28 | $33 | None |
2021: 21 services
| Return visit (30+ min) | 286 | $40,967 | $110 |
| Short return visit (20+ min) | 377 | $35,653 | $76 |
| Destruction of precancer skin growth, 1 growth | 403 | $24,941 | $47 |
| Biopsy of related skin growth, first growth | 186 | $18,554 | $87 |
| New patient visit (30+ min) | 187 | $17,668 | $94 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 20 | $13,231 | None |
| New patient visit (45+ min) | 94 | $13,019 | $139 |
| Destruction of precancer skin growth, 2-14 growths | 319 | $12,468 | $6 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 35 | $11,219 | $312 |
| Destruction of skin growth, 1-14 growths | 88 | $9,942 | $97 |
| Punch biopsy, first skin growth | 61 | $6,995 | $109 |
| Destruction of precancer skin growth, 15 or more growths | 37 | $6,775 | $144 |
| Application of light to destroy precancer skin growth | 19 | $3,327 | $145 |
| Biopsy of related skin growth, each additional growth | 47 | $2,946 | $49 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 22 | $2,656 | $121 |
| New patient visit (15+ min) | 40 | $2,433 | $61 |
| Short return visit | 29 | $1,445 | $48 |
| Telehealth originating site facility fee | 65 | $1,362 | $19 |
| Punch biopsy, each additional skin growth | 17 | $959 | $56 |
| Injection into skin growth, 1-7 growths | 18 | $932 | $37 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $23 | None |
2020: 20 services
| Return visit (30+ min) | 310 | $37,102 | $88 |
| Short return visit (20+ min) | 311 | $21,576 | $58 |
| Destruction of precancer skin growth, 1 growth | 315 | $17,113 | $43 |
| New patient visit (30+ min) | 144 | $12,794 | $89 |
| Destruction of skin growth, 1-14 growths | 121 | $11,506 | $89 |
| Biopsy of related skin growth, first growth | 133 | $9,930 | $69 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 11 | $8,936 | None |
| New patient visit (15+ min) | 148 | $8,377 | $57 |
| Destruction of precancer skin growth, 2-14 growths | 246 | $8,125 | $5 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 22 | $6,474 | $294 |
| Destruction of precancer skin growth, 15 or more growths | 35 | $5,206 | $130 |
| Punch biopsy, first skin growth | 42 | $4,182 | $97 |
| Telehealth originating site facility fee | 116 | $2,898 | $21 |
| Biopsy of related skin growth, each additional growth | 38 | $2,524 | $49 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 16 | $2,223 | $117 |
| Telephone medical discussion with physician, 11-20 minutes | 20 | $1,269 | $58 |
| Application of light to destroy precancer skin growth | 11 | $1,086 | $99 |
| Injection into skin growth, 1-7 growths | 17 | $860 | $41 |
| Punch biopsy, each additional skin growth | 14 | $820 | $51 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 14 | $27 | None |
2019: 14 services
| Return visit (30+ min) | 253 | $33,145 | $87 |
| Short return visit (20+ min) | 272 | $19,750 | $58 |
| Destruction of precancer skin growth, 1 growth | 288 | $18,696 | $47 |
| New patient visit (30+ min) | 187 | $16,177 | $87 |
| Destruction of skin growth, 1-14 growths | 99 | $10,225 | $87 |
| New patient visit (15+ min) | 176 | $9,963 | $57 |
| Biopsy of related skin growth, first growth | 129 | $9,443 | $68 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 23 | $6,800 | $296 |
| Destruction of precancer skin growth, 2-14 growths | 222 | $6,485 | $4 |
| Punch biopsy, first skin growth | 52 | $5,442 | $103 |
| Destruction of precancer skin growth, 15 or more growths | 23 | $3,548 | $127 |
| Biopsy of related skin growth, each additional growth | 32 | $1,867 | $44 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 15 | $1,779 | $119 |
| Punch biopsy, each additional skin growth | 19 | $1,099 | $52 |
2018: 9 services
| New patient visit (30+ min) | 175 | $15,671 | $90 |
| Short return visit (20+ min) | 174 | $12,170 | $60 |
| Return visit (30+ min) | 99 | $11,640 | $90 |
| Destruction of precancer skin growth, 1 growth | 183 | $11,140 | $48 |
| Destruction of skin growth, 1-14 growths | 93 | $9,695 | $96 |
| Biopsy of single growth of skin and/or tissue | 95 | $7,639 | $73 |
| New patient visit (15+ min) | 105 | $6,505 | $62 |
| Destruction of precancer skin growth, 2-14 growths | 147 | $3,206 | $4 |
| Biopsy of each additional growth of skin and/or tissue | 29 | $1,250 | $29 |
2017: 9 services
| New patient visit (30+ min) | 149 | $11,247 | $75 |
| Short return visit (20+ min) | 128 | $8,885 | $54 |
| Destruction of precancer skin growth, 1 growth | 120 | $6,752 | $45 |
| New patient visit (15+ min) | 118 | $6,565 | $56 |
| Destruction of skin growth, 1-14 growths | 55 | $4,886 | $81 |
| Biopsy of single growth of skin and/or tissue | 73 | $4,685 | $58 |
| Return visit (30+ min) | 40 | $4,552 | $86 |
| Destruction of precancer skin growth, 2-14 growths | 90 | $1,601 | $4 |
| Biopsy of each additional growth of skin and/or tissue | 16 | $468 | $28 |
2016: 5 services
| New patient visit (30+ min) | 30 | $1,985 | $66 |
| Return visit (30+ min) | 20 | $1,542 | $70 |
| Short return visit (20+ min) | 26 | $1,231 | $46 |
| Destruction of precancer skin growth, 1 growth | 15 | $663 | $41 |
| Biopsy of single growth of skin and/or tissue | 16 | $594 | $37 |
Medicaid work
$307 in 2020
Medicaid paid $307 for 18 billed services this clinician did in 2020, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Telehealth originating site facility fee | 18 | $307 |
| 2020 | 18 | 1 | 18 | $307 |
Drugs they prescribed that Part D paid
$1,865,113
Pharmacies billed $1,865,113 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,651) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
1,380 generic and 271 brand-name prescriptions · $1,865,113 in drug cost · 19 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Skyrizi | 27 | $531,576 | $19,688 |
| Dupixent | 68 | $285,671 | $4,201 |
| Humira(Cf) | 32 | $268,770 | $8,399 |
| Cosentyx (2 Syringes) | 14 | $162,433 | $11,602 |
| Dupixent | 23 | $101,028 | $4,393 |
See all 29 drugs
| Skyrizi | 27 | $531,576 | $19,688 |
| Dupixent | 68 | $285,671 | $4,201 |
| Humira(Cf) | 32 | $268,770 | $8,399 |
| Cosentyx (2 Syringes) | 14 | $162,433 | $11,602 |
| Dupixent | 23 | $101,028 | $4,393 |
| Otezla | 13 | $62,678 | $4,821 |
| Jublia | 17 | $16,263 | $957 |
| Fluorouracil | 95 | $7,021 | $74 |
| Clobetasol Propionate | 82 | $5,729 | $70 |
| Tacrolimus | 45 | $5,486 | $122 |
| Ketoconazole | 276 | $4,281 | $16 |
| Calcipotriene | 22 | $3,867 | $176 |
| Triamcinolone Acetonide | 173 | $3,145 | $18 |
| Fluocinonide | 78 | $2,637 | $34 |
| Metronidazole | 27 | $1,389 | $51 |
| Nystatin | 40 | $1,095 | $27 |
| Hydroxyzine | 42 | $921 | $22 |
| Desonide | 15 | $911 | $61 |
| Minoxidil | 96 | $894 | $9 |
| Valacyclovir | 31 | $773 | $25 |
| Betamethasone Dipropionate | 16 | $757 | $47 |
| Clindamycin Phosphate | 31 | $686 | $22 |
| Ciclopirox | 18 | $592 | $33 |
| Hydrocortisone | 113 | $542 | $5 |
| Betamethasone Diprop Augmented | 11 | $515 | $47 |
| Fluocinolone Acetonide | 13 | $461 | $35 |
| Finasteride | 22 | $263 | $12 |
| Spironolactone | 11 | $176 | $16 |
| Mupirocin | 16 | $143 | $9 |
Year by year
| 2024 | 1,651 | 535 | 0% (0) | 16% | $1,865,113 |
| 2023 | 1,314 | 419 | 0% (0) | None | $1,529,897 |
| 2022 | 1,234 | 401 | 0% (0) | 15% | $1,408,114 |
| 2021 | 1,339 | 430 | 0% (0) | 14% | $1,122,499 |
| 2020 | 1,259 | 405 | None | 17% | $1,094,967 |
| 2019 | 1,026 | 324 | 0% (0) | None | $650,438 |
| 2018 | 520 | 211 | 0% (0) | None | $177,540 |
| 2017 | 408 | 146 | None | 16% | $121,557 |
| 2016 | 82 | 45 | 0% (0) | 18% | $10,931 |
| 2015 | 21 | None | 0% (0) | None | $3,629 |
| 2014 | 16 | None | None | None | $1,831 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Humira(Cf) | 38 | $349,497 | $9,197 |
| Cosentyx Sensoready | 11 | $162,702 | $14,791 |
| Dupixent | 35 | $131,410 | $3,755 |
| Dupixent | 29 | $110,324 | $3,804 |
| Fluorouracil | 84 | $7,161 | $85 |
| Tacrolimus | 36 | $5,289 | $147 |
| Clobetasol Propionate | 52 | $4,954 | $95 |
| Ketoconazole | 216 | $4,057 | $19 |
| Fluocinonide | 62 | $3,583 | $58 |
| Triamcinolone Acetonide | 159 | $2,234 | $14 |
| Desonide | 20 | $1,241 | $62 |
| Betamethasone Dipropionate | 15 | $1,008 | $67 |
| Clindamycin Phosphate | 22 | $994 | $45 |
| Hydroxyzine | 22 | $813 | $37 |
| Valacyclovir | 14 | $615 | $44 |
| Doxycycline Hyclate | 32 | $553 | $17 |
| Minoxidil | 50 | $528 | $11 |
| Nystatin | 18 | $471 | $26 |
| Hydrocortisone | 94 | $466 | $5 |
| Clotrimazole | 13 | $455 | $35 |
| Ciclopirox | 12 | $390 | $33 |
| Dexamethasone | 11 | $280 | $25 |
| Gabapentin | 19 | $268 | $14 |
| Finasteride | 25 | $222 | $9 |
| Spironolactone | 15 | $143 | $10 |
| Prednisone | 12 | $101 | $8 |
| Mupirocin | 11 | $93 | $8 |
2022: 24 drugs
| Humira(Cf) | 37 | $346,029 | $9,352 |
| Stelara | 12 | $219,701 | $18,308 |
| Humira | 18 | $116,746 | $6,486 |
| Dupixent | 27 | $95,933 | $3,553 |
| Cosentyx (2 Syringes) | 11 | $75,222 | $6,838 |
| Fluorouracil | 73 | $6,733 | $92 |
| Ketoconazole | 230 | $5,177 | $23 |
| Fluocinonide | 71 | $4,328 | $61 |
| Clobetasol Propionate | 41 | $3,608 | $88 |
| Tacrolimus | 23 | $3,131 | $136 |
| Triamcinolone Acetonide | 147 | $1,827 | $12 |
| Betamethasone Dipropionate | 16 | $1,316 | $82 |
| Doxycycline Hyclate | 22 | $729 | $33 |
| Fluocinolone Acetonide | 11 | $673 | $61 |
| Ciclopirox | 12 | $645 | $54 |
| Hydrocortisone | 109 | $620 | $6 |
| Nystatin | 11 | $484 | $44 |
| Finasteride | 36 | $338 | $9 |
| Valacyclovir | 14 | $318 | $23 |
| Gabapentin | 20 | $239 | $12 |
| Hydroxyzine | 17 | $224 | $13 |
| Minoxidil | 29 | $222 | $8 |
| Mupirocin | 20 | $216 | $11 |
| Spironolactone | 15 | $124 | $8 |
2021: 31 drugs
| Humira(Cf) | 42 | $388,350 | $9,246 |
| Humira | 28 | $181,017 | $6,465 |
| Dupixent | 26 | $86,887 | $3,342 |
| Otezla | 18 | $65,922 | $3,662 |
| Fluorouracil | 71 | $6,204 | $87 |
| Ketoconazole | 202 | $4,846 | $24 |
| Fluocinonide | 89 | $4,596 | $52 |
| Clobetasol Propionate | 45 | $4,307 | $96 |
| Triamcinolone Acetonide | 202 | $2,762 | $14 |
| Calcipotriene | 11 | $1,884 | $171 |
| Tacrolimus | 13 | $1,607 | $124 |
| Metronidazole | 15 | $1,239 | $83 |
| Desonide | 13 | $1,186 | $91 |
| Nystatin | 18 | $1,106 | $61 |
| Imiquimod | 16 | $1,037 | $65 |
| Betamethasone Dipropionate | 15 | $1,022 | $68 |
| Ciclopirox | 21 | $826 | $39 |
| Fluocinolone Acetonide | 11 | $786 | $71 |
| Hydrocortisone | 118 | $737 | $6 |
| Betamethasone Diprop Augmented | 11 | $718 | $65 |
| Doxycycline Hyclate | 16 | $666 | $42 |
| Methotrexate | 16 | $561 | $35 |
| Hydroxychloroquine Sulfate | 12 | $477 | $40 |
| Clindamycin Phosphate | 11 | $420 | $38 |
| Nystatin-Triamcinolone | 18 | $412 | $23 |
| Gabapentin | 18 | $401 | $22 |
| Mupirocin | 28 | $316 | $11 |
| Finasteride | 19 | $251 | $13 |
| Hydroxyzine | 32 | $246 | $8 |
| Spironolactone | 12 | $215 | $18 |
| Acyclovir | 12 | $40 | $3 |
2020: 32 drugs
| Stelara | 16 | $320,147 | $20,009 |
| Humira(Cf) | 26 | $257,448 | $9,902 |
| Humira | 25 | $142,649 | $5,706 |
| Enbrel | 21 | $120,015 | $5,715 |
| Dupixent | 18 | $58,378 | $3,243 |
| Otezla | 15 | $53,375 | $3,558 |
| Jublia | 11 | $9,135 | $830 |
| Fluorouracil | 55 | $6,112 | $111 |
| Fluocinonide | 89 | $5,662 | $64 |
| Ketoconazole | 158 | $3,543 | $22 |
| Calcipotriene | 16 | $3,492 | $218 |
| Triamcinolone Acetonide | 192 | $2,767 | $14 |
| Clobetasol Propionate | 38 | $2,479 | $65 |
| Betamethasone Dipropionate | 21 | $1,555 | $74 |
| Fluocinolone Acetonide | 18 | $1,537 | $85 |
| Nystatin | 11 | $1,285 | $117 |
| Doxycycline Hyclate | 15 | $1,157 | $77 |
| Clindamycin Phosphate | 17 | $1,006 | $59 |
| Fluocinolone Acetonide | 12 | $1,003 | $84 |
| Imiquimod | 12 | $944 | $79 |
| Hydrocortisone | 131 | $867 | $7 |
| Clotrimazole | 11 | $773 | $70 |
| Dexamethasone | 16 | $680 | $43 |
| Methotrexate | 19 | $583 | $31 |
| Ciclopirox | 21 | $529 | $25 |
| Nystop | 17 | $450 | $26 |
| Gabapentin | 12 | $320 | $27 |
| Spironolactone | 13 | $288 | $22 |
| Finasteride | 17 | $205 | $12 |
| Hydroxyzine | 23 | $190 | $8 |
| Mupirocin | 20 | $164 | $8 |
| Prednisone | 23 | $128 | $6 |
2019: 24 drugs
| Stelara | 14 | $241,196 | $17,228 |
| Humira | 23 | $126,248 | $5,489 |
| Enbrel | 22 | $118,738 | $5,397 |
| Fluorouracil | 42 | $4,896 | $117 |
| Clobetasol Propionate | 44 | $4,035 | $92 |
| Calcipotriene | 16 | $3,788 | $237 |
| Fluocinonide | 53 | $3,287 | $62 |
| Triamcinolone Acetonide | 154 | $3,109 | $20 |
| Ketoconazole | 122 | $2,834 | $23 |
| Doxycycline Hyclate | 32 | $2,577 | $81 |
| Nystatin | 22 | $1,344 | $61 |
| Imiquimod | 11 | $1,104 | $100 |
| Clindamycin Phosphate | 20 | $932 | $47 |
| Fluocinolone Acetonide | 12 | $836 | $70 |
| Dexamethasone | 20 | $734 | $37 |
| Hydrocortisone | 95 | $530 | $6 |
| Ciclopirox | 16 | $494 | $31 |
| Mupirocin | 38 | $394 | $10 |
| Valacyclovir | 13 | $345 | $27 |
| Prednisone | 34 | $293 | $9 |
| Clotrimazole | 11 | $234 | $21 |
| Gabapentin | 19 | $195 | $10 |
| Finasteride | 11 | $117 | $11 |
| Hydroxyzine | 17 | $99 | $6 |
2018: 16 drugs
| Humira | 12 | $62,442 | $5,204 |
| Acitretin | 11 | $14,234 | $1,294 |
| Fluocinolone Acetonide | 22 | $2,258 | $103 |
| Fluocinonide | 30 | $2,110 | $70 |
| Ketoconazole | 69 | $1,936 | $28 |
| Fluorouracil | 19 | $1,904 | $100 |
| Clobetasol Propionate | 11 | $1,560 | $142 |
| Triamcinolone Acetonide | 73 | $1,159 | $16 |
| Clindamycin Phosphate | 21 | $1,088 | $52 |
| Metronidazole | 18 | $766 | $43 |
| Ciclopirox | 13 | $583 | $45 |
| Nystatin | 14 | $464 | $33 |
| Hydrocortisone | 54 | $424 | $8 |
| Doxycycline Hyclate | 12 | $297 | $25 |
| Mupirocin | 19 | $130 | $7 |
| Prednisone | 17 | $88 | $5 |
2017: 10 drugs
| Clobetasol Propionate | 16 | $2,825 | $177 |
| Metronidazole | 23 | $2,579 | $112 |
| Fluorouracil | 18 | $2,080 | $116 |
| Fluocinonide | 40 | $2,076 | $52 |
| Clindamycin Phosphate | 16 | $1,116 | $70 |
| Ketoconazole | 43 | $1,051 | $24 |
| Doxycycline Hyclate | 14 | $746 | $53 |
| Triamcinolone Acetonide | 47 | $736 | $16 |
| Hydrocortisone | 38 | $320 | $8 |
| Mupirocin | 20 | $180 | $9 |
2016: 2 drugs
| Triamcinolone Acetonide | 13 | $310 | $24 |
| Ketoconazole | 12 | $235 | $20 |
Money from drug and device companies
$47 in 2024
| 2024 | 1 | 3 | None | $47 |
| 2023 | 2 | 3 | None | $77 |
| 2022 | 1 | 1 | None | $34 |
| 2019 | 2 | 2 | None | $149 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| STRATA Skin Sciences | Xtrac | $47 | 3 payments
|
See all 3 published payments
| STRATA Skin Sciences | Meals · 2024-03-07 | Xtrac | $18 |
| STRATA Skin Sciences | Meals · 2024-03-05 | Xtrac | $6 |
| STRATA Skin Sciences | Meals · 2024-02-21 | Xtrac | $23 |
See earlier years (2023, 2022, 2019)
2023: $77
| Inari Medical | Flowtriever Catheter, S | $62 | 2 payments
|
| Pfizer | Cibinqo | $15 | 1 payment
|
2022: $34
| STRATA Skin Sciences | Xtrac | $34 | 1 payment
|
2019: $149
| Ucb | None | $134 | 1 payment
|
| DUSA Pharmaceuticals | Levulan Kerastick | $15 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1356617260
- Licence
- CA A126496California A126496: Current · expires 2027-03-31
- Trained
- University of California, San Francisco School of Medicine, 2012
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 450 Broadway St # B, Redwood City, CA, 94063
- NPI first listed
- 2012-03-25
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1133 E Stanley Blvd Ste 111, Livermore, CA, 94550 · 450 Broadway St # B, Redwood City, CA, 94063